Alector and GSK partnership to end after dementia, Alzheimer's drug failures

GSK terminated its neuroscience collaboration with Alector, ending coverage of two experimental antibody drugs after both candidates experienced clinical setbacks. The termination following adverse clinical results is a material negative for development progress and near-term pipeline value.

Analysis

GSK terminated its neuroscience collaboration with Alector, ending coverage of two experimental antibody drugs after both candidates experienced clinical setbacks. The termination following adverse clinical results is a material negative for development progress and near-term pipeline value.